22nd Jan 2015 08:11
SAINT HELIER (Alliance News) - Shire PLC Thursday announced a positive response from the European Decentralised Procedure or DCP for Elvanse Adult in UK, Denmark and Sweden.
The application for Elvanse Adult based on four phase 3 studies in adults with attention deficit hyperactivity disorder or ADHD was submitted in February 2014.
ADHD is a common psychiatric disorder in children, adolescents and adults. The company noted that in Europe, the choice of licensed medications for diagnosed adults with ADHD is currently limited.
Copyright RTT News/dpa-AFX
Related Shares:
Shire